NDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
CITANEST PLAIN (prilocaine hydrochloride) by AstraZeneca is mechanism of action prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 1965.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CITANEST PLAIN is a local anesthetic injection containing prilocaine hydrochloride, a small-molecule amide anesthetic approved in 1965. It works by stabilizing neuronal membranes and inhibiting ionic fluxes to block pain signal initiation and conduction. The drug is used for infiltration anesthesia, nerve blocks, and other regional anesthetic procedures.
LOE Approaching
As an aging local anesthetic nearing loss of exclusivity with moderate competitive pressure (30%), brand teams are likely focused on retention and efficiency rather than growth initiatives.
Mechanism of Action
Mechanism of Action Prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CITANEST PLAIN offers limited career advancement opportunities given the product's LOE-approaching status and absence of linked job postings. This is best suited for early-career professionals seeking operational expertise in mature portfolio management or specialists transitioning out of growth-stage roles.
Brand ManagerField Sales Representative
Worked on CITANEST PLAIN at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.